Loading clinical trials...
Loading clinical trials...
Phase III, Open-label, Switch Over Trial of the Efficacy and Safety of Agalsidase Beta Biosidus (AGA BETA BS) in Fabry Disease Patients Previously Stabilized With Fabrazyme®
Conditions
Interventions
Recombinant human alpha galactosidase A (agalsidase beta)
Recombinant human alpha-galactosidase A (agalsidase beta)
Locations
5
Argentina
Instituto de Nefrología Pergamino S.R.L
Pergamino, Buenos Aires, Argentina
Centro Médico Santa María de la Salud
San Isidro, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Quilmes
Buenos Aires, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, Argentina
Centro Oncológico Riojano Integral
La Rioja, Argentina
Start Date
December 13, 2022
Primary Completion Date
September 19, 2024
Completion Date
March 31, 2025
Last Updated
February 18, 2026
NCT06941025
NCT07382128
NCT05923788
NCT05473637
NCT07277361
NCT04252066
Lead Sponsor
Bio Sidus SA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions